Could Blockchain Ensure Integrity of Clinical Trial Data?

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy to spot any tampering with results - such as making the treatment look more effective or diminishing side effects.

"Everyone is talking about how blockchain is going to revolutionize many of the data challenges in medicine, and here is one use that finally might make sense," said Atul Butte, MD, PhD, who is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and director of the Bakar Computational Health Sciences Institute at UCSF. "We think it could someday be useful for pharma companies running clinical trials."

The research was published February 22 in Nature Communications.

Blockchain technology utilizes an old computer science technique known as hashing, which creates a unique digital signature for each so-called block of data. The hashes accumulate sequentially, as new data is entered or changed, with each block depending on the last. The resulting "blockchain" creates an audit trail for regulators that is easy to decipher and validate, even without looking at the actual data.

Daniel Wong, a PhD candidate in Biological and Medical Informatics at UCSF, built the system to operate through a web portal, so that each time new data is entered on a given trial participant, the sender, receiver, timestamp, and file attachment containing the data, along with the hash of the previous block of data pertaining to that patient, is recorded onto a new block, with its own distinct signature.

Unlike the decentralized nature of most blockchain applications, this clinical trial prototype depends on having a regulator with centralized authority, such as the U.S. Food and Drug Administration, to operate the web portal, register all parties, and keep a ledger of the blockchain's hashes.

Data, including adverse events, would be reported to the regulatory agency in real time, which may provide a boost to the safety and efficiency of clinical trials. While the prototype makes allowances for data entry or other errors to be corrected, new data can only be appended to the existing chain, without erasing what was there before.

"It makes it really obvious when someone's changing something," Wong said. "You can see who put their hands on it, who made it, who changed it, and who received it."

Wong tested the system with a small subset of data from a real, previously run phase II trial included in ImmPort, a repository of open clinical trial data funded by the National Institutes of Allergy and Infectious Diseases (NIAID) that is managed by Butte's lab and collaborators.

After entering the original data, he logged in as the trial sponsor and tried to erase adverse events that had been reported for two patients in their case report forms. Instead of deleting those reports, however, the system appended his changes to the original data, making it clear who had tried to corrupt the forms, when it was done, and what had been changed.

Wong also tried corrupting the data stored from an earlier point in the trial, when patients were assigned to different treatment arms -- drug or placebo -- to make it look as though they had been given a different medication plan. But the blockchain ledger pinpointed exactly what had changed and when.

A prototype system like this reduces risks, but does not completely protect data from tampering. Even within a system enabled with this type of blockchain technology, the authors pointed out, it is still possible that those seeing patients at the point of care could enter wrong or incorrect data at the outset.

But blockchain technology could enable trials to be conducted under challenging conditions, or open doors to data exchanges that are more secure, more efficient, and more transparent for both researchers and the general public.

"A system built upon our prototype could be developed to enable oversight of international clinical trials, for example," Butte said. "And it could be expanded to provide more access to raw data for research scientists, the way we do with ImmPort, or deliver trial results to the public."

Daniel R Wong, Sanchita Bhattacharya, Atul J Butte.
Prototype of running clinical trials in an untrustworthy environment using blockchain.
Nature Communicationsvolume 10, Article number: 917 2019. doi: 10.1038/s41467-019-08874-y.

Most Popular Now

Is Your Marketing Effective for an NHS C…

How can you make sure you get the right message across to an NHS chief information officer, or chief nursing information officer? Replay this webinar with Professor Natasha Phillips, former...

Welcome Evo, Generative AI for the Genom…

Brian Hie runs the Laboratory of Evolutionary Design at Stanford, where he works at the crossroads of artificial intelligence and biology. Not long ago, Hie pondered a provocative question: If...

We could Soon Use AI to Detect Brain Tum…

A new paper in Biology Methods and Protocols, published by Oxford University Press, shows that scientists can train artificial intelligence (AI) models to distinguish brain tumors from healthy tissue. AI...

Telehealth Significantly Boosts Treatmen…

New research reveals a dramatic improvement in diagnosing and curing people living with hepatitis C in rural communities using both telemedicine and support from peers with lived experience in drug...

AI can Predict Study Results Better than…

Large language models, a type of AI that analyses text, can predict the results of proposed neuroscience studies more accurately than human experts, finds a new study led by UCL...

Using AI to Treat Infections more Accura…

New research from the Centres for Antimicrobial Optimisation Network (CAMO-Net) at the University of Liverpool has shown that using artificial intelligence (AI) can improve how we treat urinary tract infections...

Research Study Shows the Cost-Effectiven…

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings...

New Guidance for Ensuring AI Safety in C…

As artificial intelligence (AI) becomes more prevalent in health care, organizations and clinicians must take steps to ensure its safe implementation and use in real-world clinical settings, according to an...

Remote Telemedicine Tool Found Highly Ac…

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a...

Philips Aims to Advance Cardiac MRI Tech…

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to...

Deep Learning Model Accurately Diagnoses…

Using just one inhalation lung CT scan, a deep learning model can accurately diagnose and stage chronic obstructive pulmonary disease (COPD), according to a study published today in Radiology: Cardiothoracic...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...